Prostate stem cell antigen (PSCA) and prostate-specific membrane antigen (PSMA) are utilized commonly for targeting chimeric antigen receptors for reaching the appropriate therapeutic outcomes in prostate cancer (PC) [107]. The gene discussed is FOLH1; the disease is Familial prostate cancer.